Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Melanoma 2004 detailed case study.doc

Case study tumour type: 51 year old male with melanoma
Case study tumour type: Melanoma
Medical history prior to first course of radiowave therapy (RWT) prior to 3.07.2006

Presenting symptoms
Patient is a 51 year old male who presented to his GP in 2004 with a mass in the left scapular
area.

Initial diagnosis
– February 2004 – Melanoma
Method of diagnosis – Histopathology from resected left scapula lesion (February 2004)
Morphology – Ulcerated melanoma 1.25 level IV
Stage – Clark level IV
Grade – N/A
Past medical history
High cholesterol
Investigations and treatments (prior to RWT) – treatments, imaging and blood tests

February 2004 – Surgery – Resection of mass in the left scapular area (no surgical report
available, notes taken from specialist’s letter dated 31.03.2006).
February 2004 – Histopathology from Resected Left Scapula Lesion – Confirmed Ulcerated
melanoma 1.25 level IV (no histopathology report available, notes taken from specialist’s
letter dated 31.03.2006).
June 2004 – Surgery – Elective lymph node dissection for palpable lymph glands and biopsy
performed. None of the 17 nodes had metastatic melanoma (no reports available, notes taken
from specialist’s letter dated 31.03.2006).
10.03.2006 – Surgery – Left chest wall resection of lesion below left clavicle. The melanoma
abutted the margins of excision. Pathology showed probable metastatic melanoma (no surgical
report available, notes taken from specialist’s letter dated 31.03.2006).
13.04.2006 – CT Brain – Showed no evidence of metastatic disease.
13.04.2006 – CT Neck, Chest and Abdomen – Indicated well-defined nodular lesion in left
lower lobe of lung, which measured 1.8 x 1.7cm and most likely represented metastatic
deposit. Prominent lymphadenopathy was seen in left paratracheal region with one node
measuring 2.0 x 1.5cm. Another prominent node was also noted in subcarinal region
measuring 3.0 x 1.6cm.
Radiowave Therapy – first course
From 3.07.2006 to 21.07.2006
Current medical conditions at commencement of first RWT
High cholesterol

Current medications at commencement of first RWT

Medication

Stage of disease at commencement of first RWT
Metastatic malignant melanoma with mediastinal nodes and a small volume of pulmonary
nodal disease

Interruptions to first RWT

None

Supportive therapy required during first RWT
17.07.2006 – PICC line infection, antibiotics commenced
Medication

Other treatments required during first RWT

Medical history following first course of RWT – post 21.07.2006

9 week treatment response post first RWT
19.09.2006 – CT Neck, Chest, Abdomen and Pelvis – Comparison was made with the study of
13.04.2006. Showed decrease in the size and density of the nodular lesion in left lower lung.
The largest node in left paratracheal region measured 1.3 x 0.8cm. No new metastatic lesion
was identified.
Summary of measurements of target lesions
Lesion Location
Largest node in left paratracheal region 21 week treatment response post first RWT
14.12.2006 – CT Scan – Showed essentially stable appearances with no major increase of mediastinal nodes, but possible increase in the number of mediastinal nodes. The right groin node remained stable in size and there was no major increase in the pulmonary lesions (no CT report available, notes taken from specialist’s letter dated 20.12.2006). Other treatments post first RWT
None
Radiowave Therapy – second course
From 16.04.2007 to 4.05.2007
Current medical conditions at commencement of second RWT
High cholesterol

Current medications at commencement of second RWT

Medication

Stage of disease at commencement of second RWT
Metastatic disease with mediastinal nodes and pulmonary lesions

Interruptions to second RWT

None

Supportive therapy required during second RWT
None
Other treatments required during second RWT
None
Medical history following second course of RWT – post 4.05.2007

20 week treatment response
post second RWT
20.09.2007 – CT Chest, Abdomen and Pelvis – Indicated no convincing evidence of
metastatic disease.
32 week treatment response post second RWT

13.12.2007 – Chest X-Ray – Showed no evidence of pulmonary or rib cage deposits by plain
radiography.
1 year 4 months treatment response post second RWT

11.09.2008 – CT Chest, Abdomen and Pelvis – Showed no evidence of metastatic disease.

1 year 10 months treatment response post second RWT

6.03.2009 – CT Scan – Quite stable with no evidence of progressive disease (no CT report
available, notes taken from specialist’s letter dated 6.03.2009).

Other treatments post second RWT
None
Radiowave Therapy – third course
Current medical conditions at commencement of third RWT
High cholesterol

Current medications at commencement of third RWT

Medication

Stage of disease at commencement of third RWT
No disease

Interruptions to third RWT
None

Supportive therapy required during third RWT
None
Other treatments required during third RWT
None
Medical history following third course of RWT – post 10.07.2009

9 week treatment response post third RWT


10.09.2009 – CT Head, Chest, Abdomen and Pelvis – Comparison was made with the study of
5.03.2009. Conclusion showed stable appearances (no evidence of new disease). Slightly
prominent central mediastinal lymph nodes and mesenteric nodes again were noted. The
largest lymph node in the aortopulmonary region measured 1.7 x 1cm, however these had not
changed in the past six months.
Other treatments post third RWT
None
Current status

Disease status as at 10.09.2009 CT scan showed stable disease.
Patient status as at 18.12.2009 Patient works full time and states his health is good.

Disclaimer
Any particular case study outcome does not mean that in every case the treatment of cancer using
radiowave therapy will achieve the same result

Source: http://www.radiowaveclinic.com/case_studies/Melanoma-2004-Detailed-Case-Study.pdf

Microsoft word - dgaln20058046z.doc

DE L’ALIMENTATION, DE LA PECHE ET DE LA RURALITE Direction générale de l’alimentation Sous-direction de la santé et de la protection animales Bureau de la santé animale NOTE DE SERVICE Bureau de la pharmacie vétérinaire et de l’alimentation animale DGAL/SDSPA/N2005-8046 Adresse : 251, rue de Vaugirard 75 732 PARIS CEDEX 15 Date: 11 février 2005 Suivi

Questions and answers on the review of prozac for use in children and adolescents

QUESTIONS AND ANSWERS ON THE REVIEW OF PROZAC FOR USE IN CHILDREN AND ADOLESCENTS The Committee for Medicinal Products for Human Use (CHMP) has completed its arbitration review of Prozac (fluoxetine) and associated namesextend its use in the treatment of children suffering from depression, provided that the marketing authorisation holder (MAH), Eli Lilly, carries out additional studie

Copyright © 2010-2014 Drugstore Pdf Search